A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Low Advanced or Metastatic Breast Cancer
Interventions: DRUG: SHR-A1811 & Dalpiciclib Isethionate Tablets|DRUG: SHR-A1811 & Fulvestrant|DRUG: SHR-A1811 & Bevacizumab injection
Sponsor: Jiangsu HengRui Medicine Co., Ltd.